2020
Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer
Nguyen KA, Lee A, Patel SA, Chakravorty A, Yu JB, Kishan AU, Chang AJ. Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. JAMA Network Open 2020, 3: e2017144. PMID: 32970153, PMCID: PMC7516602, DOI: 10.1001/jamanetworkopen.2020.17144.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyBody radiation therapyRadiation therapyProstate cancerIntermediate-risk prostate cancerExternal beam radiation therapyManagement of LocalizedExternal beam radiotherapyUse of brachytherapyBeam radiation therapyCohort studyBeam radiotherapyTherapyDisease managementCancerBrachytherapyPatientsRadiotherapy
2016
National sociodemographic disparities in the treatment of high‐risk prostate cancer: Do academic cancer centers perform better than community cancer centers?
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. National sociodemographic disparities in the treatment of high‐risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer 2016, 122: 3371-3377. PMID: 27434225, DOI: 10.1002/cncr.30205.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedBlack or African AmericanCancer Care FacilitiesCommunity Health ServicesDatabases, FactualDemographyFollow-Up StudiesHealthcare DisparitiesHispanic or LatinoHumansMaleMedically UninsuredNeoplasm GradingNeoplasm StagingPrognosisProstatic NeoplasmsQuality of Health CareRisk FactorsSocioeconomic FactorsUnited StatesWhite PeopleConceptsHigh-risk prostate cancerCommunity cancer centerProstate cancerAcademic cancer centerCancer CenterDefinitive therapyTreatment delayTreatment of high-risk prostate cancerAcademic centersNational Cancer Data BaseMultivariate Cox regression analysisSociodemographic disparitiesHigh-risk cancerCancer treatment patternsMultivariate Cox regressionTiming of therapyCox regression analysisMultivariate logistic analysisTreatment disparitiesCommunity centersExperience treatment delaysUninsured patientsTreatment patternsGray's testCox regressionIncorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer
Dosoretz A, Yu J. Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer. Journal Of Clinical Oncology 2016, 34: 1718-1722. PMID: 27001587, DOI: 10.1200/jco.2015.66.3237.Peer-Reviewed Original ResearchConceptsExternal-beam radiotherapyDigital rectal examinationPalpable diseaseRectal examinationGleason 3+3 diseaseOncology Grand Rounds seriesHigh-grade prostate cancerMagnetic resonance imaging-ultrasound fusionMultiparametric magnetic resonance imagingAdjacent normal prostatePositive biopsy coresUltrasound-guided biopsyInguinal hernia repairT2-weighted imagesJournal of Clinical OncologyPatient's medical historyMagnetic resonance imagingHypointense featuresGleason 4Prostate volumePSA levelsAndrogen deprivationCataract surgeryIntraprostatic lesionsBiopsy cores
2015
Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?
Mahal B, Muralidhar V, Chen Y, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Trinh Q, Nguyen P. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU International 2015, 118: 95-101. PMID: 26207642, DOI: 10.1111/bju.13239.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityGleason score 5Risk of prostate cancer-specific mortalityGleason score 4Prostate cancerScore 5Increased risk of PCSMGray competing risk regression analysisProstate cancer-specific mortality outcomesProstate cancer-specific mortality ratesScore 4Competing risk regression analysisGleason score 3Gleason score 8Gleason score 9Primary Gleason patternReference group of patientsCancer-specific mortalityAggressive treatment strategiesGroup of patientsRisk regression analysisHighest-risk patientsGleason 4Gleason scoreGleason pattern